Somnus Therapeutics Inc. Release: Phase 2 Study of SKP-1041 for Sleep Maintenance Insomnia Shows Significant Reduction of Mid-Night Awakenings without Next-Day Cognitive Impairment
6/15/2011 6:17:30 AM
More...
|
Somnus Therapeutics Inc. Seeks Buyer for Insomnia Drug that Treats Midnight Awakenings
6/15/2011 6:15:12 AM
More...
|
Somnus Therapeutics Inc. Awarded QTDP Grant for Clinical Trials of SKP-1041 Sleep Maintenance Insomnia Therapy
11/4/2010 11:14:05 AM
More...
|
Somnus Therapeutics Inc. Developing Medication to Prevent Middle-of-the-Night Awakening with No Adverse Effects on Next Day Performance
6/9/2010 10:48:44 AM
More...
|
Somnus Therapeutics Inc. Raises $15 Million
2/11/2010 7:40:58 AM
More...
|
Somnus Therapeutics Inc. Release: Presented at SLEEP 2009: New Controlled-Release Formulations of Proven Drug Being Developed for Middle-of-the-Night Awakening
6/8/2009 1:14:14 PM
More...
|
Skyepharma PLC (SKYE) And Somnus Therapeutics Inc. - Research Update
12/11/2008 10:16:30 AM
More...
|
Somnus Therapeutics Inc. Introduces Its Scientific Advisory Board
11/6/2008 12:07:53 PM
More...
|
Somnus Therapeutics Inc. Announces Initial Board of Directors
9/16/2008 8:49:53 AM
More...
|